| abstract |
Disclosed are agents and methods for treating unwanted or deleterious immune responses. More particularly, the present invention discloses neuritin agents for use in inhibiting plasma cell (PC) differentiation, reducing the number of autoreactive B cells, treating, or inhibiting the development or progression of, autoreactive B cell disorders including B cell-mediated autoimmune diseases and IgE-mediated disorders and of monoclonal gammopathies and PC dyscrasias. |